In AML, there are the United States Food and Drug Administration-approved targeted therapies; for FLT3 mutations midostaurin and gilteritinib, for IDH1/2 mutations ivosidenib and enasidenib are the choices. The gene discussed is FLT3; the disease is acute myeloid leukemia.